FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109675346> ?p ?o ?g. }

• W3109675346 endingPage "721" @default.
• W3109675346 startingPage "718" @default.
• W3109675346 abstract "Abstract Background The use of rifamycin antibiotics for TB prevention carries a risk of detrimental drug–drug interactions with concomitantly used ART. Objectives To evaluate the interaction of the antiretroviral drug nevirapine in combination with 4 weeks of daily rifapentine and isoniazid for TB prevention in people living with HIV. Methods Participants were individuals enrolled in the BRIEF-TB study receiving nevirapine and randomized to the rifapentine/isoniazid arm of the study. Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination. Nevirapine apparent oral clearance (CL/F) was estimated and the geometric mean ratio (GMR) of CL/F prior to and during rifapentine/isoniazid was calculated. Results Seventy-eight participants had evaluable PK data: 61 (78%) female, 51 (65%) black non-Hispanic and median (range) age of 40 (13–66) years. Median (IQR) nevirapine trough concentrations were: week 0, 7322 (5266–9302) ng/mL; week 2, 5537 (3552–8462) ng/mL; and week 4, 5388 (3516–8243) ng/mL. Sixty out of 78 participants (77%) had nevirapine concentrations ≥3000 ng/mL at both week 2 and 4. Median (IQR) nevirapine CL/F values were: week 0 pre-rifapentine/isoniazid, 2.03 (1.58–2.58) L/h; and during rifapentine/isoniazid, 2.62 (1.81–3.42) L/h. The GMR (90% CI) for nevirapine CL/F was 1.30 (1.26–1.33). Conclusions The CL/F of nevirapine significantly increased with concomitant rifapentine/isoniazid. The decrease in nevirapine trough concentrations during rifapentine/isoniazid therapy suggests induction of nevirapine metabolism, consistent with known rifapentine effects. The magnitude of this drug–drug interaction suggests daily rifapentine/isoniazid for TB prevention should not be co-administered with nevirapine-containing ART." @default.
• W3109675346 created "2020-12-07" @default.
• W3109675346 creator A5000852039 @default.
• W3109675346 creator A5005879554 @default.
• W3109675346 creator A5017051528 @default.
• W3109675346 creator A5024983758 @default.
• W3109675346 creator A5032814621 @default.
• W3109675346 creator A5038657323 @default.
• W3109675346 creator A5040228257 @default.
• W3109675346 creator A5044248283 @default.
• W3109675346 creator A5045831486 @default.
• W3109675346 creator A5053987417 @default.
• W3109675346 creator A5071106707 @default.
• W3109675346 creator A5078117679 @default.
• W3109675346 creator A5083035273 @default.
• W3109675346 date "2020-11-30" @default.
• W3109675346 modified "2023-10-17" @default.
• W3109675346 title "Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention" @default.
• W3109675346 cites W1981712752 @default.
• W3109675346 cites W2100139561 @default.
• W3109675346 cites W2100669275 @default.
• W3109675346 cites W2114609571 @default.
• W3109675346 cites W2134294082 @default.
• W3109675346 cites W2161786249 @default.
• W3109675346 cites W2171287195 @default.
• W3109675346 cites W2529786144 @default.
• W3109675346 cites W2921307586 @default.
• W3109675346 cites W3014021031 @default.
• W3109675346 cites W3045676066 @default.
• W3109675346 cites W3067695085 @default.
• W3109675346 doi "https://doi.org/10.1093/jac/dkaa470" @default.
• W3109675346 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7879140" @default.
• W3109675346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33241266" @default.
• W3109675346 hasPublicationYear "2020" @default.
• W3109675346 type Work @default.
• W3109675346 sameAs 3109675346 @default.
• W3109675346 citedByCount "6" @default.
• W3109675346 countsByYear W31096753462021 @default.
• W3109675346 countsByYear W31096753462022 @default.
• W3109675346 countsByYear W31096753462023 @default.
• W3109675346 crossrefType "journal-article" @default.
• W3109675346 hasAuthorship W3109675346A5000852039 @default.
• W3109675346 hasAuthorship W3109675346A5005879554 @default.
• W3109675346 hasAuthorship W3109675346A5017051528 @default.
• W3109675346 hasAuthorship W3109675346A5024983758 @default.
• W3109675346 hasAuthorship W3109675346A5032814621 @default.
• W3109675346 hasAuthorship W3109675346A5038657323 @default.
• W3109675346 hasAuthorship W3109675346A5040228257 @default.
• W3109675346 hasAuthorship W3109675346A5044248283 @default.
• W3109675346 hasAuthorship W3109675346A5045831486 @default.
• W3109675346 hasAuthorship W3109675346A5053987417 @default.
• W3109675346 hasAuthorship W3109675346A5071106707 @default.
• W3109675346 hasAuthorship W3109675346A5078117679 @default.
• W3109675346 hasAuthorship W3109675346A5083035273 @default.
• W3109675346 hasBestOaLocation W31096753462 @default.
• W3109675346 hasConcept C112705442 @default.
• W3109675346 hasConcept C126322002 @default.
• W3109675346 hasConcept C142462285 @default.
• W3109675346 hasConcept C142724271 @default.
• W3109675346 hasConcept C203014093 @default.
• W3109675346 hasConcept C2776306059 @default.
• W3109675346 hasConcept C2776967927 @default.
• W3109675346 hasConcept C2776991065 @default.
• W3109675346 hasConcept C2777975735 @default.
• W3109675346 hasConcept C2779130552 @default.
• W3109675346 hasConcept C2779806340 @default.
• W3109675346 hasConcept C2781069245 @default.
• W3109675346 hasConcept C2993143319 @default.
• W3109675346 hasConcept C3013748606 @default.
• W3109675346 hasConcept C3019249092 @default.
• W3109675346 hasConcept C501593827 @default.
• W3109675346 hasConcept C71924100 @default.
• W3109675346 hasConcept C86803240 @default.
• W3109675346 hasConcept C89423630 @default.
• W3109675346 hasConcept C98274493 @default.
• W3109675346 hasConceptScore W3109675346C112705442 @default.
• W3109675346 hasConceptScore W3109675346C126322002 @default.
• W3109675346 hasConceptScore W3109675346C142462285 @default.
• W3109675346 hasConceptScore W3109675346C142724271 @default.
• W3109675346 hasConceptScore W3109675346C203014093 @default.
• W3109675346 hasConceptScore W3109675346C2776306059 @default.
• W3109675346 hasConceptScore W3109675346C2776967927 @default.
• W3109675346 hasConceptScore W3109675346C2776991065 @default.
• W3109675346 hasConceptScore W3109675346C2777975735 @default.
• W3109675346 hasConceptScore W3109675346C2779130552 @default.
• W3109675346 hasConceptScore W3109675346C2779806340 @default.
• W3109675346 hasConceptScore W3109675346C2781069245 @default.
• W3109675346 hasConceptScore W3109675346C2993143319 @default.
• W3109675346 hasConceptScore W3109675346C3013748606 @default.
• W3109675346 hasConceptScore W3109675346C3019249092 @default.
• W3109675346 hasConceptScore W3109675346C501593827 @default.
• W3109675346 hasConceptScore W3109675346C71924100 @default.
• W3109675346 hasConceptScore W3109675346C86803240 @default.
• W3109675346 hasConceptScore W3109675346C89423630 @default.
• W3109675346 hasConceptScore W3109675346C98274493 @default.
• W3109675346 hasFunder F4320337355 @default.
• W3109675346 hasIssue "3" @default.
• W3109675346 hasLocation W31096753461 @default.

• next